ASCO 2022 Conference Coverage
J

Lecture Summary - ASCO 2022 on Long-Term Toxicities With Immune Checkpoint Inhibitor in Melanoma Patients

By ASCO 2022 Conference Coverage FEATURING Justin Tong
By ASCO 2022 Conference Coverage FEATURING Justin Tong
309 views
June 21, 2022
0 Comments
Login to view comments. Click here to Login

Related Content

AUTOPLAY
12:46
Stanford Medicine

FDA Approval of Lifileucel for Unresectable or Metastatic Melanoma: …

Feat. A. Betof Warner
13:47
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Expanding the Benefit - Dabrafenib/Tramet…

Feat. V. Subbiah
23:09
Total Health

Key Updates in Skin Melanoma

Feat. R. Seedor
06:39
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free…

Feat. J. Luke
17:39
Melanoma Bridge 2023

Major Emerging Paradigm Shifts That Will Change Melanoma Management …

Feat. A. Eggermont
24:14
Masterclasses in Dermatology

Advances in the Treatment of Melanoma

Feat. D. Fisher
05:20
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Impact of Immune Checkpoint Inhibition on…

Feat. E. Buchbinder
08:38
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "A Phase 3 Trial Comparing Fianlimab + Cem…

Feat. T. Panella
19:52
OncoAlert

Melanoma Updates: Adjuvant Therapy, Advanced Disease, Uveal Melanoma…

Feat. A. Betof Warner
21:04
Penn Medicine Abramson Cancer Center

Pediatric Melanoma

Feat. M. Jen
05:37
Melanoma Bridge 2023

COLUMBUS 7-Year Update: Encorafenib + Binimetinib vs. Vemurafenib or…

Feat. R. Dummer
08:46
Sapna Patel

Neoadjuvant Immunotherapy in the Treatment of Melanoma: What Do We K…

13:12
2023 Year in Review

Year in Review: Surgical Treatment of Acral Melanoma

Feat. M. Leventer
14:00
Melanoma Bridge 2023

Is SLN Biopsy No Longer Necessary for Patients With High-Risk Primar…

Feat. J. Luke
52:19
Winship Melanoma and Cutaneous Oncology Symposium

2024 Updates on Neoadjuvant Therapy for Resectable Melanoma

Feat. S. Patel
08:27
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "Significant Durable Response With Fianlim…

Feat. O. Hamid
30:29
NYU Langone

Updates in Treatment with Immunotherapy for Melanoma and Related Mal…

Feat. J. Weber
20:55
2023 West Oncology Conference

2023 West Oncology Conference: Melanoma Updates

Feat. M. Mooradian
04:45
Sapna Patel

Optimal Duration of Neoadjuvant Treatment in Melanoma: What We Do No…

17:38
Melanoma 2024: 34th Annual Cutaneous Malignancy Update

Beyond the Primary: Comprehensive Evaluation of the Melanoma Patient…

Feat. F. Fish